Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
102 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
Rank Status Study
21 Not yet recruiting Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Wilate
22 Recruiting Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition: Acquired Hemophilia A
Intervention: Biological: OBIZUR
23 Recruiting Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
Condition: Severe Haemophilia A
Intervention: Biological: Human cl rhFVIII
24 Recruiting An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions: Hemophilia A;   Severe Hemophilia A
Intervention: Biological: rVIII‑SingleChain
25 Recruiting Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Condition: Hemophilia A, Congenital
Intervention: Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
26 Recruiting Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
Conditions: Hemophilia A;   Factor VIII
Intervention: Drug: Recombinant VIII factor
27 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
28 Not yet recruiting Improved Factor VIII Inhibitor Evaluation
Conditions: Hemophilia;   Hemophilia A
Intervention:
29 Recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: MOD-5014
30 Recruiting An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: ALN-AT3SC
31 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
32 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
33 Recruiting BAX 826 Dose-Escalation Safety Study
Condition: Hemophilia A
Interventions: Biological: BAX 826;   Biological: Octocog alfa
34 Recruiting Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
Condition: Hemophilia A
Interventions: Drug: efmoroctocog alfa;   Drug: Factor VIII
35 Recruiting BAX 855 PK-Guided Dosing
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII
36 Recruiting Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
Condition: Hemophilia A
Intervention:
37 Recruiting BAX 802 in CHA With Inhibitors
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)
38 Recruiting BAX 855 Previously Untreated Patient (PUP)
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII
39 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
40 Recruiting Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.